NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition.

MLA

Vesting, Anna Juliane, et al. “NIK/MAP3K14 in Hepatocytes Orchestrates NASH to Hepatocellular Carcinoma Progression via JAK2/STAT5 Inhibition.” Molecular Metabolism, vol. 66, Dec. 2022, p. 101626. EBSCOhost, https://doi.org/10.1016/j.molmet.2022.101626.

APA

Vesting, A. J., Jais, A., Klemm, P., Steuernagel, L., Wienand, P., Fog-Tonnesen, M., Hvid, H., Schumacher, A.-L., Kukat, C., Nolte, H., Georgomanolis, T., Altmüller, J., Pasparakis, M., Schmidt, A., Krüger, M., Supprian, M. S., Waisman, A., Straub, B. K., Raschzok, N., … Wunderlich, F. T. (2022). NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition. Molecular Metabolism, 66, 101626. https://doi.org/10.1016/j.molmet.2022.101626

Chicago

Vesting, Anna Juliane, Alexander Jais, Paul Klemm, Lukas Steuernagel, Peter Wienand, Morten Fog-Tonnesen, Henning Hvid, et al. 2022. “NIK/MAP3K14 in Hepatocytes Orchestrates NASH to Hepatocellular Carcinoma Progression via JAK2/STAT5 Inhibition.” Molecular Metabolism 66 (December): 101626. doi:10.1016/j.molmet.2022.101626.